GLP-1 Prescription for Heart Health: A New Reason to Ask
Updated June 2026
⚡ The Heart Health Angle
The SELECT trial showed Wegovy (semaglutide 2.4mg) reduced major cardiovascular events by 20% in patients with established heart disease and overweight/obesity. This earned Wegovy an expanded FDA indication for cardiovascular risk reduction — meaning patients can now access GLP-1 medication specifically for heart protection, potentially opening insurance coverage pathways that don't exist for weight loss alone.
For most of its history, GLP-1 medication has been framed as a weight-loss or diabetes tool. The SELECT trial changed that narrative permanently. Published in 2023, SELECT demonstrated that semaglutide 2.4mg (the Wegovy dose) reduced major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% in patients with established cardiovascular disease and overweight or obesity, regardless of whether they had diabetes.
That's not a weight-loss finding. It's a cardiovascular finding. And it created a new pathway to GLP-1 access.
Why this matters for prescriptions
Insurance coverage for GLP-1 medications varies significantly by indication. Many plans that exclude coverage for "weight loss" will cover the same medication when prescribed for "cardiovascular risk reduction." The SELECT trial gave Wegovy a second FDA-approved indication that doesn't carry the "weight loss medication" label — and insurance formularies have started to distinguish between the two uses.
If you have a history of heart attack, stroke, peripheral artery disease, or revascularization, and your BMI is 27 or higher, you may qualify for Wegovy under the cardiovascular indication even if your plan explicitly excludes anti-obesity medications. Your prescriber can reference the cardiovascular indication on the prior authorization to trigger a different coverage pathway.
Talk to your provider
If you have established cardiovascular disease and overweight or obesity, ask your cardiologist or primary care provider about Wegovy specifically for cardiovascular risk reduction. Frame it as: "I understand Wegovy has an FDA-approved indication for reducing cardiovascular events in patients like me. Can we discuss whether this is appropriate for my treatment plan?"
Sesame Care
From $149/mo · FDA-approved Wegovy, Ozempic, Zepbound, Foundayo
Brand-name FDA-approved medications with insurance coordination and manufacturer savings card assistance.
Get Started → Paid linkFound Health
From $189/mo · Insurance coordination · $100 off first order
Hybrid model: insurance-first approach with compounded fallback. Their team handles prior auth, appeals, and savings card applications.
Get $100 Off → Paid linkThe heart health indication is one of the most underutilized pathways to GLP-1 access. If your cardiovascular history qualifies you, this could be the key that unlocks both the prescription and the insurance coverage.